UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference
05 Novembro 2024 - 10:00AM
Business Wire
Fireside Chat on November 12, 2024 at 3:00 PM
ET
UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to
developing and commercializing innovative solutions that treat
urothelial and specialty cancers, today announced that management
will participate in a fireside chat at the Guggenheim Securities
Healthcare Innovation Conference to take place November 11-13,
2024.
Guggenheim Securities Healthcare Innovation
Conference
Date / Time:
November 12, 2024 at 3:00 PM ET
Format:
Fireside Chat and 1x1 investor
meetings
Location:
Boston, MA
Webcast Link:
here
A live public webcast from the conference will also be available
on UroGen’s Investor Relations website. A replay will be available
on the site for approximately 90 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and
commercializing innovative solutions that treat urothelial and
specialty cancers because patients deserve better options. UroGen
has developed RTGel® reverse-thermal hydrogel, a proprietary
sustained-release, hydrogel-based platform technology that has the
potential to improve the therapeutic profiles of existing drugs.
UroGen’s sustained release technology is designed to enable longer
exposure of the urinary tract tissue to medications, making local
therapy a potentially more effective treatment option. Our first
product to treat low-grade upper tract urothelial cancer and
investigational treatment UGN-102 (mitomycin) for intravesical
solution for patients with LG-IR-NMIBC are designed to ablate
tumors by non-surgical means. UroGen is headquartered in Princeton,
NJ with operations in Israel. Visit www.UroGen.com to learn more or
follow us on X (Twitter), @UroGenPharma.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241105753655/en/
INVESTORS: Vincent Perrone Senior Director, Investor Relations
vincent.perrone@urogen.com 609-460-3588 ext. 1093
MEDIA: Cindy Romano Director, Corporate Communications
cindy.romano@urogen.com 609-460-3583 ext. 1083
UroGen Pharma (NASDAQ:URGN)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
UroGen Pharma (NASDAQ:URGN)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
